Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
The administration of monoclonal antibodies (MoAbs) can result in infusion reactions of various grades; severe reactions are seen in approximately 3% of patients after infusions of cetuximab (fatalities occur in approximately 0.1% of patients). We report a case of a patient who had a severe reaction to cetuximab (a murine MoAb) who then received panitumumab (a human MoAb) and tolerated it without any infusion reaction.